Here are the S-3 shelf registrations from Quanome Technologies, Inc. (QNME) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow QNME and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QNME filings page.
Quanome Technologies, Inc. (QNME) may offer and sell up to $120,000,000 in aggregate of common stock, preferred stock, debt securities, warrants, rights and units from time to time after effectiveness. Each offering requires a prospectus supplement. While its public float remains below $75 million, the value of public primary offerings under the shelf is limited to no more than one-third of public float in any 12-month period; reported float was approximately $29,263,425 as of October 1, 2026.
After transferring American Bear Logistics Corp.’s operations to an unrelated third party on February 12, 2026, Quanome says substantially all its existing commercial business is pharmaceutical distribution through Hupan Pharmaceutical in China. Its AI compute initiative began in September 2026 and includes an agreement to purchase 32 servers, but had no executed customer contracts or revenue; its quantum-related activities also had not generated revenue as of the prospectus date.
Quanome reported approximately US$12.7 million in aggregate funding to its PRC subsidiaries and no subsidiary dividends to the parent. It describes PRC currency and cross-border transfer restrictions as limits on moving funds. It also reported an additional 180-calendar-day period through January 4, 2027 to regain Nasdaq minimum bid-price compliance.
Quanome Technologies, Inc. (QNME) filed a pre‑effective amendment to a Form S‑3 shelf registration to offer and sell up to $120,000,000 of common stock, preferred stock, debt securities, warrants, rights and units from time to time, subject to a prospectus supplement for each takedown.
The company’s common stock trades on Nasdaq under “QNME”; the closing price was $0.3302 on September 1, 2026. As of September 2, 2026, public float was about $23.9 million, triggering the Baby Shelf Limitation that caps primary offerings to one‑third of float in any 12‑month period while float remains below $75 million.
Quanome is a Nevada holding company; substantially all current revenue comes from PRC pharmaceutical distribution through wholly owned subsidiary Hupan Pharmaceutical. The filing details extensive PRC legal, regulatory, cash‑transfer, CSRC filing and cybersecurity risks, HFCAA‑related audit risks, and notes Nasdaq minimum bid‑price deficiency and potential reverse split. The company has funded PRC subsidiaries with approximately $12.7 million and has paid no dividends.